Outlook Therapeutics, Inc. — fact timeline

Outlook Therapeutics, Inc. reported second fiscal quarter ended March 31, 2026 results: net income net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.

“Outlook Therapeutics reported net loss attributable to common stockholders of $4.5 million, or $0.05 per basic and diluted share.”

Outlook Therapeutics, Inc. terminated Prior At-The-Market Sales Agreement with BTIG, LLC valued at at-the-market offering program under which the Company could offer and sell shares of its Common Sto (effective 2026-05-12).

“In connection with entering into the Sales Agreement, the Company terminated, effective May 12, 2026, its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the “Prior Sales Agreement”) with BTIG, LLC with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $100,000,000 (the “Prior ATM Program”).”

Outlook Therapeutics, Inc. entered into At The Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $100,000,000 (effective 2026-05-13).

“On May 13, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share (“Common Stock”), from time to time through H.C. Wainwright as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the “Shares”).”

Outlook Therapeutics, Inc. reported preliminary financial results for the three months ended March 31, 2026.

“On May 13, 2026, the Company announced that, as of March 31, 2026, it had approximately $7.7 million of cash and cash equivalents, which does not include $4.5 million of net proceeds from a registered direct equity offering completed in April 2026. This amount is unaudited and preliminary, is subject to normal quarterly closing processes and accounting review, and does not present all information necessary for an understanding of the Company’s financial condition as of March 31, 2026.”

Outlook Therapeutics, Inc. amended convertible notes with Avondale Capital, LLC maturing December 31, 2026.

“In connection with the entry into the Note, we and Avondale entered into an amendment to the Avondale Note (the “Note Amendment”) to extend the maturity thereof to December 31, 2026.”

Outlook Therapeutics, Inc. incurred loan of $18,360,000 with Atlas Sciences, LLC at prime rate (as published in The Wall Street Journal) plus 3% (subject to a floor maturing 15 months after the Closing.

“On March 16, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into a Note Purchase Agreement (the “NPA”) with Atlas Sciences, LLC, a Utah limited liability company (the “Investor”), pursuant to which the Company agreed to issue to the Investor an unsecured promissory note with an original principal balance of $18,360,000 (the “Note”).”

Outlook Therapeutics, Inc. amended Note Amendment with Avondale Capital, LLC (effective 2026-03-16).

“In connection with the entry into the Note, we and Avondale entered into an amendment to the Avondale Note (the “Note Amendment”) to extend the maturity thereof to December 31, 2026.”

Outlook Therapeutics, Inc. entered into Note Purchase Agreement with Atlas Sciences, LLC valued at $18,360,000 (effective 2026-03-16).

“On March 16, 2026, Outlook Therapeutics, Inc. (the “Company”) entered into a Note Purchase Agreement (the “NPA”) with Atlas Sciences, LLC, a Utah limited liability company (the “Investor”), pursuant to which the Company agreed to issue to the Investor an unsecured promissory note with an original principal balance of $18,360,000 (the “Note”).”

Outlook Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 18, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accord”

Outlook Therapeutics, Inc.: Increased authorized shares of common stock from 60,000,000 to 260,000,000 (effective 2025-03-11).

“the Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 60,000,000 to 260,000,000 shares. The increase in the authorized number of shares of the Company’s common stock was effected pursuant to a Certificate of Amendment of the Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on March 11, 2025 and was effective as of such date.”

Outlook Therapeutics, Inc. incurred convertible notes of face amount of $33,100,000 with Avondale Capital, LLC at prime rate (as published in the Wall Street Journal) plus 3% (subject to a floor maturing July 1, 2026.

“On January 31, 2025, Outlook Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Avondale Capital, LLC, a Utah limited liability company (the “Lender”), pursuant to which, the Company agreed to issue to the Lender an unsecured convertible promissory note with a face amount of $33,100,000 (the “Note”).”

Outlook Therapeutics, Inc. announced a restructuring with charges of approximately $ 0.3 million (5 people, or approximately 23% of the Company’s existing headcount).

“eligibility for severance benefits is contingent upon execution of a general release of claims against the Company. The Company estimates that it will incur approximately $ 0.3 million in restructuring charges in connection with the workforce reduction, consisting of cash-based expenses related to employee severance and notice period payments, benefits and”

Outlook Therapeutics, Inc. reported financial results for second quarter of fiscal year 2024.

“Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2024”

Outlook Therapeutics, Inc.: Effected a 1-for-20 reverse stock split and proportionate reduction in authorized shares of Common Stock via Certificate of Amendment to the Amended and Restated Certificate of Incorporation (effective 2024-03-13).

“Effective March 13, 2024 at 5:00 p.m. Eastern Time, the Company effected a 1-for-20 reverse stock split and proportionate reduction in the number of authorized shares of Common Stock pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation”

Outlook Therapeutics, Inc.: Increased authorized common stock from 425,000,000 to 1,200,000,000 shares (effective 2024-03-07).

“the stockholders of Outlook Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 425,000,000 to 1,200,000,000 shares.”

Outlook Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2024-03-07 meeting.

“Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers”

Outlook Therapeutics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm at the 2024-03-07 meeting.

“Stockholders ratified the selection by the Audit Committee of the Board of KPMG LLP as the Company’s independent registered public accounting firm”

Outlook Therapeutics, Inc. shareholders approved Amendment to effect reverse stock split at ratio of 1-for-10 to 1-for-30 and reduction in authorized shares at the 2024-03-07 meeting.

“Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock, and a reduction in the number of authorized shares of common stock, at a ratio of 1-for-10 to 1-for-30”

Outlook Therapeutics, Inc. shareholders rejected Amendment to reflect new Delaware law provisions regarding officer exculpation at the 2024-03-07 meeting.

“Stockholders did not approve the amendment of the Company’s Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation”

Outlook Therapeutics, Inc. shareholders approved Amendment to increase authorized shares from 425,000,000 to 1,200,000,000 at the 2024-03-07 meeting.

“Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 425,000,000 to 1,200,000,000 shares”

Outlook Therapeutics, Inc. shareholders approved Approval of potential issuance in excess of 19.99% of outstanding common stock upon conversion of convertible note at the 2024-03-07 meeting.

“Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock upon the conversion of an outstanding convertible note”

Outlook Therapeutics, Inc. shareholders approved Approval of potential issuance in excess of 19.99% of outstanding common stock in private placement at the 2024-03-07 meeting.

“Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock in a private placement”

Outlook Therapeutics, Inc. shareholders approved Election of Class II directors at the 2024-03-07 meeting.

“Stockholders elected each of the following nominees to serve as Class II directors on the Company’s Board of Directors”

Outlook Therapeutics, Inc. reported first fiscal quarter ended December 31, 2023 results: net income $11.2 million, EPS $0.04 per basic and diluted share.

“For the fiscal first quarter ended December 31, 2023, Outlook Therapeutics reported a net loss attributable to common stockholders of $11.2 million, or $0.04 per basic and diluted share”

Outlook Therapeutics, Inc. entered into Registration Rights Agreement with the Investors (effective 2024-01-22).

“Also on January 22, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investors”

Outlook Therapeutics, Inc. entered into Securities Purchase Agreement with the institutional and accredited investors named therein valued at $60 million (effective 2024-01-22).

“On January 22, 2024, Outlook Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the institutional and accredited investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, and the Investors agreed to purchase, in a private placement (the “Private Placement”) an aggregate of $60 million in shares”

Outlook Therapeutics, Inc. updated its guidance (reaffirmed).

“Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU”

Terry Dagnon was appointed as Senior Advisor at Outlook Therapeutics, Inc..

“Terry Dagnon ceased to serve as the Company’s Chief Operations Officer and an executive officer of the Company and was appointed as Senior Advisor.”

Outlook Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“October 16, 2023, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 32 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capital Market. In accorda”

Outlook Therapeutics, Inc. reported financial results for third fiscal quarter ended June 30, 2023.

“On August 14, 2023, Outlook Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for its third fiscal quarter ended June 30, 2023.”

Outlook Therapeutics, Inc. terminated Prior Sales Agreement with H.C. Wainwright & Co. valued at at-the-market offering agreement dated as of March 26, 2021, with aggregate offering price of up to (effective 2023-05-15).

“In connection with entering into the Sales Agreement, the Company terminated, effective May 15, 2023, its at-the-market offering agreement, dated as of March 26, 2021 (the “Prior Sales Agreement”) with H.C. Wainwright & Co. with respect to an at-the-market offering program under which the Company could offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to $40,000,000 (the “Prior ATM Program”).”

Outlook Therapeutics, Inc. entered into Sales Agreement with BTIG, LLC valued at aggregate offering price of up to $100,000,000 (effective 2023-05-16).

“On May 16, 2023, Outlook Therapeutics, Inc. (the “Company”) entered into an at-the-market-sales agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”), pursuant to which the Company may issue and sell shares of its common stock, $0.01 par value per share (“Common Stock”), from time to time through BTIG as sales agent and/or principal having an aggregate offering price of up to $100,000,000 (the “Shares”).”

Outlook Therapeutics, Inc. reported financial results for second fiscal quarter ended March 31, 2023.

“On May 15, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2023.”

Outlook Therapeutics, Inc.: Increased authorized common stock from 325,000,000 to 425,000,000 shares (effective 2023-03-29).

“The increase in the authorized number of shares of the Company’s common stock was effected pursuant to a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on March 29, 2023 and was effective as of such date.”

Outlook Therapeutics, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-03-29 meeting.

“Proposal 5. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 149,547,132 6,158,044 443,549 57,646,435”

Outlook Therapeutics, Inc. shareholders approved Ratification of KPMG, LLP as independent registered public accounting firm for fiscal year ending September 30, 2023 at the 2023-03-29 meeting.

“Proposal 4. Stockholders ratified the selection by the Audit Committee of the Board of KPMG, LLP as the Company’s independent registered public accounting firm for its fiscal year ending September 30, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 213,073,357 413,007 308,796 N/A”

Outlook Therapeutics, Inc. shareholders approved Approval of potential issuance in excess of 19.99% of outstanding common stock upon conversion of convertible note at less than minimum price under Nasdaq Listing Rule 5635 at the 2023-03-29 meeting.

“Proposal 3. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock upon the conversion of an outstanding convertible note at less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the convertible note. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 150,990,564 4,744,516 413,645 57,646,435”

Outlook Therapeutics, Inc. shareholders approved Amendment to increase authorized common stock from 325,000,000 to 425,000,000 shares at the 2023-03-29 meeting.

“Proposal 2. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 325,000,000 shares to 425,000,000 shares. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 149,648,555 6,186,516 313,654 57,646,435”

Outlook Therapeutics, Inc. shareholders approved Election of Class I directors at the 2023-03-29 meeting.

“Proposal 1. Stockholders elected each of the following nominees to serve as Class I directors on the Company’s Board of Directors (the “Board”) until the Company’s 2026 Annual Meeting of Stockholders or until his successor has been duly elected and qualified. The voting results for such nominees were as follows: Director Name Votes For Votes Withheld Broker Non- Votes Yezan Haddadin 154,190,768 1,957,957 57,646,435 Kurt J. Hilzinger 154,253,585 1,895,140 57,646,435 Faisal G. Sukhtian 153,447,079 2,701,646 57,646,435”

Outlook Therapeutics, Inc.: Increased authorized number of shares of common stock from 325,000,000 to 425,000,000 (effective 2023-03-29).

“At the 2023 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of Outlook Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 325,000,000 shares to 425,000,000 shares.”

Outlook Therapeutics, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2023-03-29 meeting.

“Proposal 5. Stockholders approved a non-binding advisory vote on the compensation of the Company’s named executive officers. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 149,513,547 6,158,044 443,547 57,646,437”

Outlook Therapeutics, Inc. shareholders approved Ratification of selection of KPMG, LLP as independent registered public accounting firm for fiscal year ending September 30, 2023 at the 2023-03-29 meeting.

“Proposal 4. Stockholders ratified the selection by the Audit Committee of the Board of KPMG, LLP as the Company’s independent registered public accounting firm for its fiscal year ending September 30, 2023. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 213,039,770 413,008 308,797 N/A”

Outlook Therapeutics, Inc. shareholders approved Approval of potential issuance in excess of 19.99% of outstanding common stock upon conversion of outstanding convertible note at less than minimum price under Nasdaq Listing Rule 5635 at the 2023-03-29 meeting.

“Proposal 3. Stockholders approved the potential issuance in excess of 19.99% of the Company’s outstanding common stock upon the conversion of an outstanding convertible note at less than the “minimum price” under Nasdaq Listing Rule 5635, if required pursuant to the terms of the convertible note. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 150,956,979 4,744,515 413,644 57,646,437”

Outlook Therapeutics, Inc. shareholders approved Amendment of Amended and Restated Certificate of Incorporation to increase authorized common stock from 325,000,000 to 425,000,000 shares at the 2023-03-29 meeting.

“Proposal 2. Stockholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of its common stock authorized for issuance from 325,000,000 shares to 425,000,000 shares. The voting results were as follows: Votes For Votes Against Abstentions Broker Non- Votes 201,885,740 9,957,794 425,182 1,492,860”

Outlook Therapeutics, Inc. shareholders approved Election of Class I directors at the 2023-03-29 meeting.

“Proposal 1. Stockholders elected each of the following nominees to serve as Class I directors on the Company’s Board of Directors (the “Board”) until the Company’s 2026 Annual Meeting of Stockholders or until his successor has been duly elected and qualified. The voting results for such nominees were as follows: Director Name Votes For Votes Withheld Broker Non- Votes Yezan Haddadin 154,157,182 1,942,892 57,646,437 Kurt J. Hilzinger 154,220,000 1,881,346 57,646,437 Faisal G. Sukhtian 153,413,493 2,536,786 57,646,437”

Outlook Therapeutics, Inc. reported fiscal first quarter ended December 31, 2022 results: net income $18.7 million, or $0.08 per basic and diluted share, EPS $0.08 per basic and diluted share.

“On February 14, 2023, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its first fiscal quarter ended December 31, 2022.”

Outlook Therapeutics, Inc. reported financial results for fiscal year ended September 30, 2022.

“On December 29, 2022, Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its fourth fiscal quarter and year ended September 30, 2022.”

Outlook Therapeutics, Inc. entered into Engagement Letter with M.S. Howells & Co. (the “Placement Agent”) (effective 2022-12-22).

“Pursuant to a letter agreement dated as of December 22, 2022 (the “Engagement Letter”), the Company engaged M.S. Howells & Co. (the “Placement Agent”) to act as placement agent with respect to certain accredited investors in the Offering.”

Outlook Therapeutics, Inc. entered into Purchase Agreements with certain institutional and accredited investors, including GMS Ventures and Investments, an affiliate of the Company valued at approximately $25 million (effective 2022-12-23).

“On December 23, 2022, Outlook Therapeutics, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”), including GMS Ventures and Investments, an affiliate of the Company, pursuant to which the Company agreed to sell and issue, in a registered direct offering, an aggregate of 28,460,831 shares (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a purchase price of $0.8784 per share, for aggregate gross proceeds to the Company of approximately $25 million”

Outlook Therapeutics, Inc. entered into Securities Purchase Agreement with Streeterville Capital, LLC valued at $31,820,000 unsecured convertible promissory note, reflecting an original issue discount of $1,800,0 (effective 2022-12-22).

“On December 22 2022, Outlook Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Streeterville Capital, LLC, a Utah limited liability company (the “Lender”), and, pursuant to the SPA, issued to the Lender an unsecured convertible promissory note with a face amount of $31,820,000 (the “Note”), reflecting an original issue discount of $1,800,000, for gross proceeds of approximately $30 million after deducting the Lender’s transaction costs covered by the Company in connection with the issuance.”